EU expands reach of Vertex’ CF drug Kalydeco
Kalydeco is the only approved medicine in Europe to treat the underlying cause of cystic fibrosis in patients with the R117H mutation
Read More
Tag: Kadcyla
NICE backs Roche’s Kadcyla for HER2-positive early breast cancer
Around 800 people will be eligible for treatment with Kadcyla
Read More
Roche submits FDA supplemental biologics license application for Kadcyla
Roche has submitted a supplemental biologics license application in the US seeking to expand the use of Kadcyla to include the adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment.
Read More
Roche’s Kadcyla cuts risk of breast cancer recurrence after surgery
Roche’s Kadcyla was significantly better than Herceptin at reducing the risk of breast cancer recurrence in certain patients with residual disease after surgery, according to new study findings presented at the San Antonio Breast Cancer Symposium.
Read More
Roche’s Kadcyla shows promise in early breast cancer
Roche has announced that its antibody drug conjugate Kadcyla cut the risk of disease recurrence when given after neoadjuvant treatment and surgery to certain breast cancer patients with residual disease.
Read More
Major u-turn sees Roche’s Kadcyla backed for NHS use
In a major turnaround Roche’s Kadcyla will now become routinely available on the NHS to some patients with breast cancer after a confidential deal was reached between the drug giant and NHS England.
Read More
SMC u-turn backs Roche’s Kadcyla for breast cancer
Women in Scotland will be among the first in the UK to have routine NHS access to Roche’s breast cancer drug Kadcyla after a landmark u-turn by cost regulators endorsed funding for the drug.
Read More
NICE backs Roche’s Perjeta, but bars Kadcyla
Patients with certain forms of breast cancer should be able to get routine NHS access to Roche’s Perjeta in England and Wales in the next three months following a recent final nod from NICE, but Kadcyla has been rejected by the cost regulator.
Read More
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
